VITROLIFE AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 168 SEK | -7.84% |
|
-11.58% | -13.71% |
| Apr. 18 | Nordic Stocks Closed Down Thursday; Arjo Series B Fell Furthest | DJ |
| Apr. 18 | Transcript : Vitrolife AB, Q1 2024 Earnings Call, Apr 18, 2024 |
| Sales 2024 * | 3.77B 344M | Sales 2025 * | 4.11B 375M | Capitalization | 22.75B 2.08B |
|---|---|---|---|---|---|
| Net income 2024 * | 594M 54.2M | Net income 2025 * | 705M 64.33M | EV / Sales 2024 * | 6.19 x |
| Net Debt 2024 * | 578M 52.75M | Net cash position 2025 * | 169M 15.42M | EV / Sales 2025 * | 5.49 x |
| P/E ratio 2024 * |
39.2
x | P/E ratio 2025 * |
32.6
x | Employees | 1,102 |
| Yield 2024 * |
0.7% | Yield 2025 * |
0.84% | Free-Float | 55.39% |
More Fundamentals
* Assessed data
More news
Latest transcript on Vitrolife AB
More press releases
More news
| 1 day | -7.84% | ||
| 1 week | -9.29% | ||
| Current month | -16.42% | ||
| 1 month | -14.42% | ||
| 3 months | -2.15% | ||
| 6 months | +18.39% | ||
| Current year | -13.71% |
1 week
159.90
194.80
1 month
159.90203.40
Current year
159.90205.40
1 year
123.90244.20
3 years
123.90585.00
5 years
112.30585.00
10 years
18.50585.00
| Managers | Title | Age | Since |
|---|---|---|---|
Bronwyn Brophy
CEO | Chief Executive Officer | - | 23-07-31 |
Patrik Tolf
DFI | Director of Finance/CFO | 54 | 21-12-31 |
| Chairman | 68 | 15-05-06 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 53 | 19-05-01 | |
| Chairman | 68 | 15-05-06 | |
| Director/Board Member | 64 | 18-04-26 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.37% | 233 M€ | +7.09% | ||
| 0.02% | 773 M€ | -.--% | - | |
| 0.01% | 10 M€ | -3.35% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-18 | 168 | -7.84% | 514,461 |
| 24-04-17 | 182.3 | -2.30% | 64,211 |
| 24-04-16 | 186.6 | -2.30% | 208,256 |
| 24-04-15 | 191 | +0.63% | 76,544 |
| 24-04-12 | 189.8 | -0.11% | 78,062 |
Delayed Quote Nasdaq Stockholm, April 18, 2024 at 11:29 am EDT
More quotes
Vitrolife AB is a Sweden-based company engaged in assisted reproduction services. The Companyâs product portfolio comprises G-RINSE, which is a solution for rinsing of contact materials, EmbryoGlue, which is a human albumin recombinant, ASP, which is a solution for oocyte retrieval and rinsing, and Semen VTS, which is a viscosity treatment system, among others. It also provides a range of procedural solutions for sperm preparation, vitrification, embryo transfer and oocyte retrieval, such as temperature control, condition control, gamete-safe labware and embryo support. The Company is active in Australia, China, France, Italy, Japan, the United States and the United Kingdom, among others, and conducts its business through a number of subsidiaries, such as Vitrolife Ltd., Vitrolife Pty Ltd., and A.T.S. Srl.
Calendar
2024-04-25
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
168
SEK
Average target price
246.7
SEK
Spread / Average Target
+46.83%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -13.71% | 2.25B | |
| -1.59% | 12.58B | |
| -17.62% | 6.82B | |
| -3.93% | 5.14B | |
| -6.68% | 4.22B | |
| +0.53% | 4.21B | |
| -48.27% | 3.47B | |
| +7.09% | 2.65B | |
| -3.40% | 1.69B | |
| -12.04% | 1.48B |
- Stock Market
- Equities
- VITR Stock
